Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $18.25.

Several research firms have commented on AMLX. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. HC Wainwright increased their target price on Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th.

Amylyx Pharmaceuticals Trading Down 0.2%

Shares of AMLX stock opened at $14.10 on Thursday. The company’s fifty day simple moving average is $13.44 and its 200-day simple moving average is $12.71. Amylyx Pharmaceuticals has a 52 week low of $2.60 and a 52 week high of $17.49. The company has a market cap of $1.55 billion, a PE ratio of -7.83 and a beta of -0.31.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 136,193 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the transaction, the chief executive officer owned 3,378,621 shares in the company, valued at $45,915,459.39. The trade was a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Camille L. Bedrosian sold 6,580 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $14.35, for a total transaction of $94,423.00. Following the completion of the transaction, the insider directly owned 175,756 shares of the company’s stock, valued at approximately $2,522,098.60. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 157,783 shares of company stock valued at $2,122,808. 12.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $25,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $45,000. BNP Paribas Financial Markets grew its position in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $47,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.